150 related articles for article (PubMed ID: 37698883)
1. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports.
Moog S; Lamartina L; Bani MA; Al Ghuzlan A; Friboulet L; Italiano A; Lacroix L; Postel Vinay S; Tselikas L; Deschamps F; Bonnet B; Pani F; Baudin E; Hadoux J
Thyroid; 2023 Nov; 33(11):1368-1373. PubMed ID: 37698883
[No Abstract] [Full Text] [Related]
2. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Di Molfetta S; Dotto A; Fanciulli G; Florio T; Feola T; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():667784. PubMed ID: 33935977
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
7. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
8. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
10. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
11. Metastatic medullary thyroid carcinoma: a new way forward.
Angelousi A; Hayes AR; Chatzellis E; Kaltsas GA; Grossman AB
Endocr Relat Cancer; 2022 May; 29(7):R85-R103. PubMed ID: 35521769
[TBL] [Abstract][Full Text] [Related]
12. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
13. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
14. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680929
[TBL] [Abstract][Full Text] [Related]
15. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
16. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma in children: current state of the art and future perspectives.
Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N
J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Hadoux J; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
[TBL] [Abstract][Full Text] [Related]
20. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
